Chairman Zhaoxian in Jinling
Release time:
2020-07-22
Zhaoxian in Jinling
News 11# July 10 , Chairman of the Group Company and Chairman of the Pharmaceutical Company Jiang Xiaomeng went to Nanjing in person to hold a special recruitment seminar at China Pharmaceutical University, attracting many senior students who are about to graduate from the pharmacy major of the university.
China Pharmaceutical University, located in the ancient capital of Nanjing, is a "211 Project" directly under the Ministry of Education and a national "Double First-class" construction university with a long history and a high reputation in the pharmaceutical field. The predecessor of the school was the National School of Pharmacy Junior College, which was founded in 1936 . It is the first pharmacy institution of higher learning founded by the state in China. 80 For more than 18 years, the school has been adhering to the school motto of "Jingye Jiqun" and has made important contributions to promoting the development of national health and health. It is considered by the industry to be the best university for pharmacy. Since its establishment, Jianfeng Pharmaceutical Company has established a close cooperative relationship with China Pharmaceutical University to jointly carry out new drug research and development and personnel training. At present, there is no shortage of talents from China Pharmaceutical University among the management backbones at all levels of the peak.
In the keynote speech of the seminar, Jiang Xiaomeng introduced the current basic situation and future development ideas of Jianfeng Group and Jianfeng Pharmaceutical, and focused on the issues that fresh graduates are most concerned about. The salary and welfare system, management structure, talent career promotion mechanism, internal training and training, and talent career development planning of Jianfeng enterprises are highlighted. Jiang Xiaomeng said that as an enterprise, it most needs talents who can stay, have good character, good comprehensive quality, and strong practical working ability, and likes talents with a sense of responsibility and teamwork spirit; as employees, they must have enterprises, workshops, and teams in mind. If you recognize the corporate culture and work hard, you will definitely develop.
Jiang Xiaomeng's speech aroused great interest among college students, and some even submitted employment agreements on the spot.
China Pharmaceutical University attached great importance to this lecture. Wang Zhenghua, Deputy Secretary of the Party Committee and Vice President of Pharmaceutical University, Sun Hongbin, Changjiang Scholar, Du Wenqing, Director of Student Affairs, Liu Shengli, Director of Employment Department, and Zhu Xiong, Director of Pharmaceutical and Chemical Institute, attended the lecture site to participate in the interaction. Wang Zhenghua said in his speech at the scene that Jianfeng Group has always attached importance to knowledge and talents, and hopes that aspiring college students will go to Jianfeng Pharmaceutical to develop and realize their life value.
11 January 13 , inspired by the lecture, a group of fresh graduates majoring in pharmacy, pharmaceutical engineering, traditional Chinese medicine and other specialties of China Pharmaceutical University made a special trip to Jinhua to learn about the spike on the spot. In the exhibition hall of the group headquarters, they learned about the development history of the peak, the situation of various industrial sectors and the corporate culture. At the headquarters of the pharmaceutical company, Jin Huazhong, secretary of the party Committee of the pharmaceutical company, gave a detailed introduction to the basic situation of the pharmaceutical company and various honors won over the years. In Jianfeng Pharmaceutical Factory, the students visited Jinxi Factory, Production Workshop and Central Laboratory. During the visit and exchange, the students of Pharmaceutical University praised Jianfeng Group and Jianfeng Pharmaceutical for their environmental management, equipment and technology level and effective management, and said one after another that they would consider joining Jianfeng Group. (Jin Huazhong Jiang Wenqing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page